SYGNIS AG / Key word(s): Financing/Acquisition
02-May-2018 / 16:41 CET/CEST
Heidelberg, Germany and Cambridge, UK, 2 May 2018 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), today announces that it has obtained debt finance to complete the acquisition of the Australian TGR Biosciences PTY LTD. As announced the completion of the transaction was dependent thereon.
SYGNIS has the right to exchange the debt finance (interest and repayment include variable elements) into a mandatory convertible bond with additional option rights for approx. 1.4 mio shares. The volume of the convertible bond and the conversion price will depend upon market conditions at the time SYGNIS exercises such right if SYGNIS decides to do so, which is likely.
Waldhofer Str. 102
Tel. +49 6221 3540 125
|Waldhofer Str. 104|
|Phone:||+49 (0) 6221 3540 125|
|Fax:||+49 (0) 6221 3540 127|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|End of Announcement||DGAP News Service|